CSS
KLRS

Cubist Systematic Strategies’s Kalaris Therapeutics KLRS Stock Holding History

Cubist Systematic Strategies’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-869
Closed -$16.2K – 3668
2024
Q3 		$16.2K Sell
869
-1,297
-60% -$22.7K ﹤0.01% 2830
2024
Q2 		$36K Buy
2,166
+1,308
+152% +$23.1K ﹤0.01% 2736
2024
Q1 		$14.9K Sell
858
-307
-26% -$5.01K ﹤0.01% 3491
2023
Q4 		$18.2K Buy
1,165
+577
+98% +$22.8K ﹤0.01% 3359
2023
Q3 		$29.1K Buy
588
+33
+6% +$2.25K ﹤0.01% 3069
2023
Q2 		$43.4K Buy
555
+536
+2,821% +$50.9K ﹤0.01% 3110
2023
Q1 		$1.76K Sell
19
-1,138
-98% -$145K ﹤0.01% 3795
2022
Q4 		$136K Sell
1,157
-721
-38% -$122K ﹤0.01% 3728
2022
Q3 		$341K Buy
1,878
+392
+26% +$61.1K ﹤0.01% 3448
2022
Q2 		$133K Buy
1,486
+304
+26% +$31.9K ﹤0.01% 3869
2022
Q1 		$183K Buy
1,182
+255
+28% +$50.9K ﹤0.01% 3081
2021
Q4 		$276K Buy
927
+165
+22% +$76.5K ﹤0.01% 2851
2021
Q3 		$439K Sell
762
-441
-37% -$204K 0.01% 2124
2021
Q2 		$546K Sell
1,203
-1,333
-53% -$688K 0.01% 1951
2021
Q1 		$1.36M Buy
+2,536
New +$2.13M 0.02% 1311

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's KLRS Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Kalaris Therapeutics (KLRS) in Q4 2024, closing a stake of 869 shares — an estimated $16.2K sold.

Cubist Systematic Strategies first reported a position in KLRS in Q1 2021 and held it in 15 quarters. The position peaked at $1.36M in Q1 2021. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Kalaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 869 Kalaris Therapeutics shares in Q4 2024, an estimated $16.2K.
  • Cubist Systematic Strategies first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 15 quarters.
  • Cubist Systematic Strategies's Kalaris Therapeutics position peaked at $1.36M in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.